Ventana PD-L1 (SP142) Assay

被引：0
|
作者：
McGill, Rachel [1 ]
Michail, Ramez [1 ]
Miller, Brianne [1 ]
Milton, Erica [1 ]
Musyoka, Agnes [1 ]
Musyoka, Rhoda [1 ]
O'Conner, Jada [1 ]
Ogunnaike, Morenike [1 ]
Omeke, Soteria [1 ]
Franklin, Gallop [1 ]
Honeywell, Marlon S. [1 ]
机构：
[1] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Inst Publ Hlth, Tallahassee, FL 32307 USA
来源：
US PHARMACIST | 2022年 / 47卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：42 / 44
页数：3
相关论文
共 50 条
  • [21] Comparison of PD-L1 Immunostain Concordance of SP263 and SP142 Across Different Tumor Types
    Nakasaki, Manando
    Fadare, Oluwole
    Patel, Sandip
    Hansel, Donna
    LABORATORY INVESTIGATION, 2017, 97 : 532A - 532A
  • [22] PD-L1 (SP142) Immunohistochemistry in Clinical Metastatic Breast Carcinomas and its Association with Survival
    Shafi, Saba
    Challa, Bindu
    Parwani, Anil
    Li, Zaibo
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 192 - 194
  • [23] PD-L1 status by SP142 and sp263 immunohistochemistry in triple-negative breast cancer
    Cordoba, A.
    Mercado, M. D. R.
    Amat, I.
    Beloqui, R.
    Aguiar, B.
    Rodriguez, Y.
    Guerrero-Setas, D.
    VIRCHOWS ARCHIV, 2020, 477 : S44 - S44
  • [24] Comparison of PD-L1 Immunostain Concordance of SP263 and SP142 Across Different Tumor Types
    Nakasaki, Manando
    Fadare, Oluwole
    Patel, Sandip
    Hansel, Donna
    MODERN PATHOLOGY, 2017, 30 : 532A - 532A
  • [25] PD-L1 IHC validation and comparison of E1L3N & SP142 mAbs in melanoma
    Schats, K.
    van Vre, E.
    De Schepper, S.
    Neyns, B.
    De Meester, I.
    Kockx, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 8 - 8
  • [26] Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
    Sung Gwe Ahn
    Seon-Kyu Kim
    Jonathan H. Shepherd
    Yoon Jin Cha
    Soong June Bae
    Chungyeul Kim
    Joon Jeong
    Charles M. Perou
    Breast Cancer Research and Treatment, 2021, 188 : 165 - 178
  • [27] PD-L1 expression of 742 newly diagnosed advanced respiratory and digestive system tumours in China based on SP142 assay.
    Chen, Yanhui
    Wang, Yating
    Yang, Bohang
    Hu, Ying
    Zeng, Hui
    Zhang, Henghui
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers
    Eva Compérat
    André Oszwald
    Gabriel Wasinger
    Justine Wacquet
    Morgan Rouprêt
    Olivier Cussenot
    World Journal of Urology, 2021, 39 : 4067 - 4071
  • [29] Utilization of Commercial SP142 PD-L1 Testing of Breast Carcinomas at a Large Academic Cancer Center
    Wong, Serena
    Reisenbichler, Emily
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 164 - 165
  • [30] Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer
    Jiankun He
    Xinran Wang
    Lijing Cai
    Zhanli Jia
    Chang Liu
    Xuemei Sun
    Si Wu
    Chunyan Ding
    Zi Zhang
    Yueping Liu
    Diagnostic Pathology, 18
12345